Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine. The foundation seed funded the company to develop a low cost, broad coverage pneumococcus vaccine.
Investment Date: June 2014